【摘要】 目的 探讨恩替卡韦联合经导管肝动脉化疗栓塞(TACE)治疗乙肝相关晚期肝癌的临床疗效。方法 入组2019年1月至2021年12月郑州大学第一附属医院收治的给予TACE治疗的乙肝相关晚期肝癌患者95例，根据是否联合应用恩替卡韦分为治疗组和对照组，其中治疗组50例接受恩替卡韦联合TACE治疗，对照组45例单纯接受TACE治疗，比较2组治疗前后血清谷丙转氨酶(ALT)、总胆红素(TBIL)、甲胎蛋白(AFP)、乙肝病毒(HBV)DNA水平。结果 治疗组乙肝相关晚期肝癌患者总有效率为90.00%,高于对照组的66.67%,差异有统计学意义(χ~2=7.758,P=0.005)。治疗组乙肝相关晚期肝癌患者血清ALT、TBIL、AFP、HBV DNA水平均低于对照组，差异均有统计学意义(t=4.329,P<0.001;t=2.913,P=0.005;t=5.957,P<0.001;t=12.099,P<0.001)。结论 恩替卡韦能够有效改善乙肝相关晚期肝癌患者的肝功能，并减少体内病毒含量，有助于患者的预后改善。更多还原

【Abstract】 Objective To explore the clinical efficacy of entecavir combined with transcatheter arterial chemoembolization(TACE) for advanced hepatocellular carcinoma with hepatitis B. Methods Ninety-five patients with advanced hepatocellular carcinoma related to hepatitis B who received TACE treatment at the First Affiliated Hospital of Zhengzhou University from January 2019 to December 2021 were enrolled and divided into the treatment group and the control group according to whether they received entecavir or not. The treatment group consisted of 50 patients who received entecavir combined with TACE treatment, and the control group consisted of 45 patients who received TACE treatment alone. The serum levels of alanine aminotransferase(ALT), total bilirubin(TBIL), alpha-fetoprotein(AFP), and hepatitis B virus(HBV) DNA were compared before and after treatment between the two groups. Results The overall response rate of patients with late-stage hepatocellular carcinoma related to hepatitis B in the treatment group was 90.00%, which was higher than that in the control group(66.67%), and the difference was statistically significant(χ~2=7.758, P=0.005). The serum levels of ALT, TBIL, AFP, and HBV DNA in patients with advanced hepatocellular carcinoma with hepatitis B in the treatment group were lower than those in the control group, and the differences were statistically significant(t=4.329, P<0.001; t=2.913, P=0.005; t=5.957, P<0.001; t=12.099, P<0.001). Conclusion Entecavir can effectively improve liver function and reduce viral load in patients with advanced hepatocellular carcinoma with hepatitis B, which is conducive to improving their prognosis.更多还原